Alembic lands US launch for generic Synthroid into a $1.87bn market
Final USFDA approval lets Alembic sell immediately into the biggest thyroid-drug market in the US. The addressable market is more than double the company’s annual revenue.
— 2 earlier stories on Alembic Pharmaceuticals Ltd. →What's new
- Alembic gets final USFDA approval for generic Levothyroxine Sodium, a copy of AbbVie's Synthroid.
- The drug targets a US market worth $1.87 billion and can launch immediately.
- It is the second major US approval in a short period, following a tentative nod for Darolutamide.
Why this matters
For a company with ~₹7,345 cr in annual revenue, even a sliver of a $1.87 billion market is a major earnings event. The final approval allows immediate launch, so revenue could appear as soon as the next quarter. The size of the market versus Alembic's own sales base makes this a forcing function for analyst model revisions.
What we're watching
- Initial market share and pricing Alembic can secure against established generic competitors.
- Any paragraph IV litigation that could delay the launch.
- How quickly this approval contributes to quarterly US revenue figures.
The full read
Alembic Pharmaceuticals can now sell a generic version of AbbVie's Synthroid in the US, entering one of the biggest drug markets it has ever tackled. The $1.87 billion addressable market for Levothyroxine Sodium tablets is more than double the company's own annual revenue of ₹7,345 crore. Even modest market share would move the needle on earnings. This is a final approval, so Alembic can launch immediately and start booking sales. It follows the tentative approval for Darolutamide, and bumps the company's total to 239 ANDAs, with 220 now final. For a mid-cap pharma, winning access to a nearly $2 billion product category is the kind of event that forces model revisions. The open question is how fast Alembic can commercialize against entrenched competitors.
Questions answered
- What exactly did Alembic get approved to sell?
- Generic versions of Levothyroxine Sodium tablets, used as thyroid hormone replacement therapy. The drug is a copy of AbbVie's brand-name Synthroid and will be available in 12 strengths, from 25 mcg to 300 mcg.
- How big is the opportunity relative to Alembic's existing business?
- The total US market for the drug is estimated at $1.87 billion. Alembic's entire annual revenue is about ₹7,345 crore (roughly $880 million). Capturing even a single-digit percentage share would meaningfully boost its top line.
- Can Alembic start selling the drug right away?
- Yes. This is a final approval, not a tentative one, so there are no remaining regulatory hurdles to a commercial launch in the US.
- How does this affect Alembic's total US pipeline?
- The company now holds 239 ANDA approvals from the USFDA, of which 220 are final. This approval for Levothyroxine follows the recent tentative approval for Darolutamide, adding another significant product to its near-term US launch list.
Story so far
All notes on APLLTD →- 22 May 2026 · 11:00 AM IST Alembic lands US launch for generic Synthroid into a $1.87bn market
- today Alembic lands generic Haldol approval, but the US market is tiny
- 15d ago Alembic sets FY27 revenue growth target at low double digits